糖尿病性潰瘍治療の世界市場規模：治療別、タイプ別、エンドユーザー別、地域別、範囲および予測

糖尿病性潰瘍治療の市場規模と予測

糖尿病性潰瘍治療市場規模は、2023年に91億7,000万米ドルと評価され、2024年から2031年にかけて5.40%のCAGRで成長し、2031年には134億4,000万米ドルに達すると予測されます。糖尿病性潰瘍は、主に糖尿病患者の足や下肢に生じる慢性の創傷です。これらの潰瘍は、末梢神経障害や血行不良などの問題の結果として形成され、身体の創傷治癒能力を低下させる。糖尿病性潰瘍の治療には、創傷ケア、感染管理、血糖管理、創傷被覆材、剥離、成長因子などの高度な治療を含む集学的戦略が用いられます。重症の場合は、回復を促し切断などの合併症を避けるために外科的介入や高気圧酸素療法が必要になることもあります。

世界の糖尿病罹患率の増加により、効率的な糖尿病性潰瘍治療に対する需要は劇的に増加すると思われます。バイオテクノロジーと再生医療の進歩は、生体工学による代用皮膚、幹細胞治療、革新的な創傷治癒剤など、この分野の技術革新を促進しています。

創傷治療管理における遠隔医療と人工知能の統合は、遠隔モニタリングや個別の治療戦略を可能にし、患者の転帰を改善する可能性を秘めています。ヘルスケアシステムが予防対策と早期介入にシフトするにつれ、糖尿病性潰瘍治療市場は、特にアジア太平洋や北米など糖尿病人口が増加している地域で拡大すると予想されます。

糖尿病性潰瘍治療の世界市場力学

世界の糖尿病性潰瘍治療市場を形成している主な市場力学

主な市場促進要因

糖尿病の有病率の増加：

国際糖尿病連合によると、糖尿病の罹患者数は2021年には世界で約5億3,700万人、2045年には7億8,300万人に達すると予測されています。糖尿病は創傷治癒を阻害するため、慢性潰瘍の発生頻度が高くなり、感染症や切断などの関連問題も発生するため、この増加は糖尿病性潰瘍治療に対する需要を押し上げています。糖尿病人口の増加に伴い、リスクを軽減し患者の転帰を向上させる効果的な創傷治療に対する需要も増加しています。

高齢化人口の増加：

世界保健機関（WHO）は、60歳以上の高齢者の数が2020年の10億人から2030年には14億人に増加すると予測しています。糖尿病とその結果である創傷治癒不良や糖尿病性潰瘍は、加齢による循環や免疫機能の変化により高齢者に多く見られます。高齢者人口の増加に伴い、この年齢層における慢性創傷とそれに伴う結果のリスクの増加に対応するため、効率的な潰瘍治療ソリューションに対する需要が高まると思われます。

ヘルスケア支出の増加：

特に新興国におけるヘルスケア支出の増加が、糖尿病性潰瘍治療市場を促進しています。世界銀行のデータによると、GDPに占める世界の医療費の割合は2000年の9.2%から2018年には9.8%に増加しています。この支出の増加により、革新的な治療法へのアクセス拡大、ヘルスケアインフラの強化、創傷ケアの管理向上が可能になります。医療予算が拡大するにつれ、糖尿病性潰瘍治療などの慢性疾患管理により多くの資源が投入されるようになり、専門的治療や新規治療への患者アクセスが向上しています。

主な課題

感染リスクの高さ：

糖尿病性潰瘍は感染リスクが高く、治療を複雑にし、回復を遅らせる可能性があります。抗生物質耐性の問題が深刻化していることもこの問題を悪化させ、感染症の適切な管理を困難にしています。このため、治療期間と治療費が長期化し、現在の医薬品の有効性と市場成長が制限されることになります。

先端治療薬の規制障壁：

幹細胞、遺伝子治療、バイオ人工皮膚などの先端医薬品は、規制当局の厳しい承認が必要です。長くて費用のかかる承認プロセスは、新規治療法の市場導入を妨げます。規制上のハードルは、患者の救命につながる可能性のある治療へのアクセスを妨げ、市場の成長を制限しています。

高い治療費：

バイオエンジニアリングによる代用皮膚や幹細胞治療など、進行した糖尿病性潰瘍の治療費は、特に低開発国の多くの患者にとって高すぎる可能性があります。このような高額な治療費は、ヘルスケアシステムや患者が治療費を捻出するのに苦労するため、受容を制限し、市場全体の成長に影響を与えます。

治癒プロセスの遅さ：

糖尿病性潰瘍は一般的に、血行不良と高血糖のために治癒が遅いです。治癒速度の遅れは治療期間と治療費を増加させ、医療制度にさらなる負担をかけるとともに、効果的な治療ソリューションの拡張性を制限し、市場の成長を阻害します。

主要動向：

創傷治療技術の進歩：

バイオエンジニアリングによる代用皮膚、成長ホルモン、幹細胞治療などの創傷治療技術の進歩は、糖尿病性潰瘍の治療効率を高める。これらの技術は治癒を早め、感染リスクを低下させ、患者の予後を改善するため、先進的な創傷治療システムを使用する医療従事者が増えるにつれて市場開拓が進みます。

遠隔医療の普及：

遠隔医療は遠隔地からの患者モニタリングや創傷評価を可能にするため、糖尿病性潰瘍治療で普及しつつあります。この動向は遠隔地に住む患者や頻繁に通院できない患者にとって特に有利です。遠隔医療はその利便性とアクセスの良さから採用されており、患者のコンプライアンスを向上させ、早期介入を可能にします。

創傷治療における人工知能（AI）の統合：

人工知能（AI）は糖尿病性潰瘍管理にますます活用されるようになっており、創傷治癒結果の予測、治療経過の追跡、オーダーメイドの治療戦略の推奨においてヘルスケア臨床医を支援しています。AIは診断精度と治療効果を向上させ、患者ケア全体の強化と治療方法の合理化によって市場成長をもたらします。

目次

第1章 世界の糖尿病性潰瘍治療市場のイントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• 検証
• プライマリーインタビュー
• データソース一覧

第4章 糖尿病性潰瘍治療の世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 糖尿病性潰瘍治療の世界市場：治療別

• 概要
• 創傷被覆材
• 創傷ケアデバイス
• 活性療法

第6章 糖尿病性潰瘍治療の世界市場：タイプ別

• 概要
• 足潰瘍
• 口腔潰瘍
• 皮膚潰瘍

第7章 糖尿病性潰瘍治療の世界市場：エンドユーザー別

• 概要
• 病院および診療所
• 外来手術センター
• 学術・研究機関

第8章 糖尿病性潰瘍治療の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第9章 世界の糖尿病性潰瘍治療市場：競合情勢

• 概要
• 各社の市場ランキング
• 主な発展戦略

第10章 企業プロファイル

• ConvaTec Group Plc
• Smith & Nephew Plc
• 3M Company
• Molnlycke Health Care AB
• Coloplast AS
• B. Braun SE
• Medline Industries LP
• MiMedx Group Inc.
• Organogenesis Inc.
• URGO Medical

第11章 主な発展

• 製品上市／開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第12章 付録

• 関連調査

Diabetic Ulcers Treatment Market Size And Forecast

Diabetic Ulcers Treatment Market size was valued at USD 9.17 Billion in 2023 and is projected to reach USD 13.44 Billion by 2031, growing at a CAGR of 5.40% from 2024 to 2031. Diabetic ulcers are chronic wounds that primarily affect the feet and lower extremities of diabetics. These ulcers form as a result of issues such as peripheral neuropathy and poor circulation, which reduce the body's capacity to heal wounds properly. Diabetic ulcers are treated using a multidisciplinary strategy that includes wound care, infection control, glucose management, and advanced therapies such as wound dressings, debridement, and growth factors. In severe situations, surgical intervention or hyperbaric oxygen therapy may be necessary to promote recovery and avoid complications such as amputation.

The increased prevalence of diabetes globally, the demand for efficient diabetic ulcer therapies is likely to increase dramatically. Biotechnology and regenerative medicine advancements are driving innovation in the field, including bioengineered skin substitutes, stem cell therapies, and innovative wound healing agents.

The integration of telemedicine and artificial intelligence in wound care management has the potential to improve patient outcomes by allowing for remote monitoring and individualized treatment strategies. As healthcare systems shift toward preventative measures and early interventions, the market for diabetic ulcer therapy is expected to grow, particularly in regions with growing diabetes populations, such as Asia-Pacific and North America.

Global Diabetic Ulcers Treatment Market Dynamics

The key market dynamics that are shaping the global diabetic ulcers treatment market include:

Key Market Drivers:

Increasing Prevalence of Diabetes:

The rising incidence of diabetes is a primary driver of the diabetic ulcer treatment market, with roughly 537 million adults affected globally in 2021 and a predicted 783 million by 2045, according to the International Diabetes Federation. This increase has driven up demand for diabetic ulcer treatments since diabetes hinders wound healing, resulting in a higher frequency of chronic ulcers and associated problems such as infections and amputations. As the diabetes population expands, so will the demand for effective wound care treatments to mitigate risks and enhance patient outcomes.

Growing Aging Population:

The growing aging population is a major driver of the diabetic ulcer treatment market, with the World Health Organization predicting that the number of individuals aged 60 and over will increase from 1 billion in 2020 to 1.4 billion by 2030. Diabetes and its consequences, such as poor wound healing and diabetic ulcers, are more common in older persons due to changes in circulation and immunological function caused by aging. As the older population grows, the demand for efficient ulcer treatment solutions will rise to meet the increased risk of chronic wounds and accompanying consequences in this age range.

Increasing Healthcare Expenditure:

Increasing healthcare expenditure, particularly in emerging nations, is propelling the diabetic ulcer treatment market. According to World Bank data, global health expenditure as a proportion of GDP increased from 9.2% in 2000 to 9.8% in 2018. This increased spending enables greater access to innovative treatments, enhanced healthcare infrastructure, and better wound care management. As healthcare budgets expand, more resources are directed into chronic disease management, such as diabetic ulcer treatments, improving patient access to specialized care and novel therapies.

Key Challenges:

High Risk of Infection:

Diabetes ulcers have a high risk of infection, which can complicate therapy and slow recovery. The growing issue of antibiotic resistance exacerbates this problem, making it difficult to properly manage infections. This lengthens treatment times and expenses, restricting the efficacy of current medicines and market growth.

Regulatory Barriers for Advanced Therapies:

Advanced medicines such as stem cells, gene therapy, and bioengineered skin substitutes are subject to demanding regulatory approval. Long and expensive approval processes impede the introduction of novel treatments to the market. Regulatory hurdles impede patient access to potentially life-saving treatments, limiting market growth.

High Treatment Costs:

Treatment costs for advanced diabetic ulcers, including bioengineered skin substitutes and stem cell therapies, might be too expensive for many patients, particularly in underdeveloped nations. The high cost of these treatments limits acceptance and has an impact on overall market growth, as healthcare systems and patients struggle to afford them.

Slow Healing Process:

Diabetic ulcers typically heal slowly due to poor circulation and high blood sugar levels. The delayed rate of healing increases the length and cost of care, putting additional strain on healthcare systems and restricting the scalability of effective treatment solutions, stifling market growth.

Key Trends:

Advances in Wound Care Technologies:

Advances in wound care technology, including bioengineered skin substitutes, growth hormones, and stem cell therapies, enhance the efficiency of diabetic ulcer treatments. These technologies promote faster healing, lower infection risks, and improve patient outcomes, resulting in market development as more healthcare providers use advanced wound treatment systems.

Increasing Adoption of Telemedicine:

Telemedicine is gaining traction in diabetic ulcer treatment as it allows for remote patient monitoring and wound assessment. This trend is especially advantageous for patients who live in remote areas or are unable to travel frequently to the clinic. Telemedicine is being adopted due to its convenience and accessibility, which improves patient compliance and allows for early intervention.

Integration of Artificial Intelligence (AI) in Wound Care:

Artificial Intelligence (AI) is increasingly being used in diabetic ulcer management, assisting healthcare clinicians in predicting wound healing outcomes, tracking treatment progress, and recommending tailored care strategies. AI improves diagnostic accuracy and treatment efficacy, resulting in market growth by enhancing overall patient care and streamlining treatment methods.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Diabetic Ulcers Treatment Market Regional Analysis

Here is a more detailed regional analysis of the global diabetic ulcers treatment market:

North America:

North America currently dominates the global diabetic ulcer treatment market, which is projected to continue in the coming years. One of the primary factors is the high incidence of diabetes in the region, with the Centers for Disease Control and Prevention (CDC) claiming that 37.3 million Americans, or 11.3% of the population, had diabetes in 2021. This figure is expected to increase rapidly, reaching 60.6 million by 2060.

The region has a higher-than-average incidence of diabetic foot ulcers, with a 2022 study in the Journal of the American Medical Association (JAMA) indicating an annual rate of 2.2%, which is projected to rise to 2.5% by 2030. These causes, combined with an aging population, increase the patient pool as older persons are more susceptible to diabetes and accompanying problems.

North America's strong healthcare infrastructure and significant research investments are also driving market expansion. In 2020, the National Institutes of Health (NIH) will invest USD 1.15 Billion in diabetes research, promoting innovation in therapies for diabetic complications such as ulcers. Rising healthcare spending in the United States, expected to reach USD 6.2 Trillion by 2028, supports further investment in advanced ulcer therapies. These characteristics, together with a growing older population and continuing advances in medical technology, are driving North America's leadership in the diabetic ulcer treatment market.

Asia Pacific:

The Asia Pacific region's fastest-growing to the top of the list for diabetic ulcer treatment markets. One of the key factors is the region's increasing prevalence of diabetes, notably in China and India. According to the International Diabetes Federation's (IDF) Diabetes Atlas 2021, the Western Pacific area had 206 million adults with diabetes in 2021, with the amount expected to climb to 260 million by 2045. This increase dramatically raises the number of individuals at risk of acquiring diabetic complications including foot ulcers, which currently afflict millions.

Furthermore, increased healthcare expenditure and improved healthcare infrastructure are important drivers driving market expansion. According to the World Health Organization (WHO), health spending in the Asia Pacific region has grown at an average annual rate of 6.7%, outperforming economic development, while countries such as China seek to expand healthcare spending to 7% of GDP by 2030. The region's vast and aging population also plays an important role, with the number of persons aged 60 and up predicted to more than double by 2050. This demographic shift, together with increased knowledge of diabetic complications and improved healthcare access, positions the Asia-Pacific area as an essential market for diabetic ulcer therapy in the coming years.

Global Diabetic Ulcers Treatment Market: Segmentation Analysis

The Global Diabetic Ulcers Treatment Market is Segmented on the basis of Treatment, Type, End-User, And Geography.

Diabetic Ulcers Treatment Market, By Treatment

• Wound Care Dressings
• Wound Care Devices
• Active Therapies

Based on Treatment, the market is bifurcated into Wound Care Dressings, Wound Care Devices, and Active Therapies. Wound care dressings dominate as they are widely used to treat a variety of ulcers, including diabetic foot ulcers. Hydrocolloid, foam, and antimicrobial dressings serve to keep the healing environment wet, lower the risk of infection, and promote faster recovery. Active therapies are the fastest-growing area, due to advances in bioengineered skin substitutes, growth factors, and stem cell therapies, which provide more effective options for difficult-to-heal diabetic ulcers, especially in cases when conventional treatments are ineffective.

Diabetic Ulcers Treatment Market, By Type

• Foot Ulcer
• Mouth Ulcer
• Skin Ulcer

Based on Type, the market is segmented into Foot Ulcer, Mouth Ulcer, and Skin Ulcer. The foot ulcer segment is currently dominant due to the high frequency of diabetic foot ulcers among diabetics, which is exacerbated by variables such as neuropathy and poor circulation, all of which increase the risk of foot injuries and infections. The mouth ulcer segment is expanding at a rapid pace, owing to increased knowledge and better diagnostic procedures for diabetic oral complications, as well as an increase in lifestyle-related variables contributing to oral health problems. This development reflects a larger recognition of the need to address all types of ulcers in diabetes individuals in order to enhance overall health.

Diabetic Ulcers Treatment Market, By End-User

• Hospitals And Clinics
• Ambulatory Surgical Centers
• Academic and Research Organizations

Based on End-User, the market is segmented into Hospitals and Clinics, Ambulatory Surgical Centers, and Academic and Research Organizations. Hospitals and clinics dominate the market, owing to their extensive healthcare offerings, superior wound care facilities, and access to specialized medical professionals capable of effectively managing severe diabetic ulcer patients. This component is essential for providing inpatient and outpatient care, guaranteeing a comprehensive approach to treatment. Ambulatory surgery facilities are the fastest-growing group, driven by an increasing desire for outpatient operations, cost-effectiveness, and a growing demand for minimally invasive therapies. These centers are becoming increasingly popular for wound management and ulcer surgery, indicating a shift toward more accessible and efficient patient care.

Key Players

• The "Global Diabetic Ulcers Treatment Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• ConvaTec Group Plc, Smith & Nephew Plc, 3M Company, Coloplast AS, B. Braun SE, Medline Industries LP, MiMedx Group, Inc., Organogenesis Inc., URGO Medical, Healthium Medtech, Molnlycke Healthcare, Paul Hartmann AG, and Systagenix Wound Management.
• The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Diabetic Ulcers Treatment Market Recent Developments
• In April 2023, 3M Health Care's revolutionary 3M Veraflo therapy, which includes both 3M Veraflo cleanse choice complete dressing and 3M V.A.C. Veraflo cleanse choice dressing, obtained FDA approval for the hydromechanical removal of infectious materials, non-viable tissue, and wound debris. This enabled the company to expand its treatment type offers and launch new treatment types into the market.
• In June 2022, Smith & Nephew will launch a new R&D and manufacturing facility in Hull, UK, for its advanced wound treatment franchise. This strategy enabled the corporation to expand its research operations and enhance its production capacity

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL DIABETIC ULCERS TREATMENT MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL DIABETIC ULCERS TREATMENT MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL DIABETIC ULCERS TREATMENT MARKET, BY TREATMENT

• 5.1 Overview
• 5.2 Wound Care Dressings
• 5.3 Wound Care Devices
• 5.4 Active Therapies

6 GLOBAL DIABETIC ULCERS TREATMENT MARKET, BY TYPE

• 6.1 Overview
• 6.2 Foot Ulcer
• 6.3 Mouth Ulcer
• 6.4 Skin Ulcer

7 GLOBAL DIABETIC ULCERS TREATMENT MARKET, BY END-USER

• 7.1 Overview
• 7.2 Hospitals and Clinics
• 7.3 Ambulatory Surgical Centers
• 7.4 Academic and Research Organizations

8 GLOBAL DIABETIC ULCERS TREATMENT MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL DIABETIC ULCERS TREATMENT MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 ConvaTec Group Plc
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Smith & Nephew Plc
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 3M Company
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Molnlycke Health Care AB
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Coloplast AS
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 B. Braun SE
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Medline Industries LP
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 MiMedx Group Inc.
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Organogenesis Inc.
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 URGO Medical
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 Appendix

• 12.1 Related Research